

## ImpediMed Ltd - Appendix 4E

ABN 65 089 705 144

### Preliminary final report

Current Financial Period Ended: 30 June 2008  
Previous Corresponding Reporting Period: 30 June 2007\*\*

The information contained in this document should be read in conjunction with the ImpediMed Limited Financial Report for the year ended 30 June 2008 and any public announcements made by ImpediMed Limited and its controlled entities during the year in accordance with continuous disclosure obligations arising under the ASX Listing Rules.

\*\*The Group has elected to provide the results from the audited financial statements of the previous corresponding period prior to ASX listing for increased comparative data.

#### 1 Results for announcement to the market

	Current reporting period \$	Previous corresponding period \$	
1.1 Revenue from ordinary activities	2,994,285	1,418,832	
Increase (decrease) in revenue:			1,575,453
Percentage increase (decrease):			111%
<p>Note : The increase in revenue from ordinary activities, is attributable to two significant effects (1) an increase in medical business revenues from \$1,185k to \$1,407k; and (2) the addition of a Test and Measurement Division which in the nine months following acquisition contributed \$1,110k in revenues.</p>			
1.2 Profit/(loss) from ordinary activities after tax attributable to members	(9,754,128)	(17,014,748)	
Increase/(decrease) in loss from ordinary activities after tax attributable to members:			(7,260,620)
Percentage increase/(decrease):			(40)%
<p>Note : The most significant driver of the decrease in the loss from ordinary activities after tax attributable to members is a reduction in interest expense on convertible notes and preference shares from \$10,145k in 2007 to \$1,682k in 2008. This expense related to discounts on conversion of the convertible notes and preference shares to other equity instruments, and was not interest in the conventional sense. The 2008 expense predated the company's IPO.</p>			
1.3 Net profit/(loss) for the period attributable to members	(9,754,128)	(10,126,577)	
Increase/(decrease) in net loss for the period attributable to members:			(372,449)
Percentage increase/(decrease):			4%

Note : The net loss for the period attributable to members was down 4% for 2008 versus 2007. There are two out of the ordinary effects which counterbalanced one another in 2007, namely the interest effect outlined above (-\$8,463k) and a profit on the demerger of a discontinued operation (the cardiology division) of \$6,888k. These effects had a negative impact of -1575K on 2007, so adjusting for these factors, the business generated an increased loss by \$1,203k, which primarily reflects the increases in overheads to support the market expansion in the US. The directors report provides further analysis with respect to the results.

<b>2</b>	<b>Dividends</b>		
2.1	Dividends	NIL	NIL
	There were no dividends declared and paid during the reporting period on ordinary shares. There were no dividends proposed and not yet recognised as a liability during the reporting period.		
2.2	Dividend Record Date	Not applicable	

<b>3</b>	<b>Net tangible assets per ordinary security</b>		
		Current reporting period \$	Previous corresponding period \$
	Net tangible assets	8,974,148	(17,973,101)
	Issued share capital at reporting date	50,809,291	11,151,629
		Current reporting period	Previous corresponding period
	Number of shares on issue at reporting date	81,718,857	22,789,361
	Net tangible assets per ordinary security	0.11	(0.79)

<b>4</b>	<b>Earnings per security</b>		
		Current reporting period	Previous corresponding period
	Weighted average number of ordinary shares (excluding reserved shares) for basic earnings per share	65,288,401	20,120,598
	<i>Effect of dilution:</i>		
	Share options	12,174,636	1,963,000
	Weighted average number of ordinary shares (excluding reserved shares) adjusted for the effect of dilution	77,463,037	22,083,598
		Current reporting period	Previous corresponding period
	Loss per share from continued operations		
	Basic EPS	(0.15)	(0.85)
	Loss per share from profit attributable to ordinary shares		
	Basic EPS	(0.15)	(0.50)
	Diluted earnings per share has been determined to be the same as basic earnings per share as the actual calculation is anti-dilutive for both periods presented. The instruments considered in the calculations of diluted earnings per share include convertible notes, preference shares, share options and performance shares.		
	Refer to <i>Note 11</i> on page 56 of the attached Financial Report for additional information pertaining to EPS for the current reporting period.		

**5 Acquisitions and divestments**

- 5.1 Entity Acquired : ImpediMed Ltd acquired 100% of the shares of Xitron Technologies, Inc.-- a San Diego, California based company
- 5.2 Date of Acquisition 1st October 2007
- 5.3 Xitron Technologies Inc had a \$384K net loss for the reporting period and accounted for 3.8% of the total Group net  
If the acquisition had taken place at the beginning of the current reporting period, Xitron's contribution to the total Group net loss would have been 4.3%.
- 5.4 Entity Dissolved: ImpediMed Ltd's subsidiary organisation, Mesa Acquisition Corp, ceased to exist as of the date of acquisition of Xitron Technologies, Inc.
- 5.5 Date of Dissolution: 1st October 2007
- 5.6 Mesa Acquisition Corp was established for the sole purpose of facilitating the acquisition of the US based Xitron Technologies Inc.